A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1
Latest Information Update: 21 Dec 2021
At a glance
- Drugs Brodalumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms AMVISION-1
- Sponsors Amgen; Bausch Health Companies
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 26 Oct 2020 Primary endpoint (American College of Rheumatology (ACR) 20 response) has been met according to the results published in the Annals of the Rheumatic Diseases
- 26 Oct 2020 Pooled analysis results from AMVISION-1 and AMVISION-2 studies were published in the Annals of the Rheumatic Diseases